rs137852240
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PM2PM5PP3_StrongPP5_Very_Strong
The NM_000133.4(F9):c.676C>T(p.Arg226Trp) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R226Q) has been classified as Pathogenic.
Frequency
Consequence
NM_000133.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 16 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
F9 | NM_000133.4 | c.676C>T | p.Arg226Trp | missense_variant | 6/8 | ENST00000218099.7 | |
F9 | NM_001313913.2 | c.562C>T | p.Arg188Trp | missense_variant | 5/7 | ||
F9 | XM_005262397.5 | c.547C>T | p.Arg183Trp | missense_variant | 5/7 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
F9 | ENST00000218099.7 | c.676C>T | p.Arg226Trp | missense_variant | 6/8 | 1 | NM_000133.4 | P1 | |
F9 | ENST00000394090.2 | c.562C>T | p.Arg188Trp | missense_variant | 5/7 | 1 | |||
F9 | ENST00000643157.1 | n.1343C>T | non_coding_transcript_exon_variant | 4/7 |
Frequencies
GnomAD3 genomes ? Cov.: 23
GnomAD4 exome Cov.: 31
GnomAD4 genome ? Cov.: 23
ClinVar
Submissions by phenotype
Hereditary factor IX deficiency disease Pathogenic:4
Pathogenic, criteria provided, single submitter | clinical testing | Center for Genomic Medicine, King Faisal Specialist Hospital and Research Center | Apr 04, 2024 | - - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Dec 15, 1989 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Nov 22, 2022 | Variant summary: F9 c.676C>T (p.Arg226Trp) results in a non-conservative amino acid change located in the Serine proteases, trypsin domain (IPR001254) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 183448 control chromosomes (gnomAD). c.676C>T has been reported in the literature in multiple individuals affected with Factor IX Deficiency (Hemophilia B) (examples: Ludwig_1992, Hamasaki-Katagiri_2012, Branchini_2021). These data indicate that the variant is very likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function. The most pronounced variant effect results in <10% of normal activity (example: Branchini_2021). Other variants affecting the same amino acid (e.g R226Q, R226G) has been reported in patients with severe form of Hemophila B (Hamasaki-Katagiri_2012, Branchini_2021 and HGMD). Two clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 and classified the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Genetics and Molecular Pathology, SA Pathology | Apr 22, 2021 | - - |
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital | Aug 15, 2023 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Apr 04, 2020 | The F9 c.676C>T; p.Arg226Trp variant (rs137852240), also known as 20518C>T, is reported in the literature in multiple individuals affected with moderate to severe hemophilia B (see link to Factor IX database and references therein, Chavali 2009, Hamasaki-Katagiri 2012). This variant is reported in ClinVar (Variation ID: 10590), and is absent from general population databases (Exome Variant Server, Genome Aggregation Database), indicating it is not a common polymorphism. The arginine at codon 226 lies at the cleavage site in the activation peptide and is highly conserved. Computational analyses (SIFT, PolyPhen-2) predict that this variant is deleterious. Additionally, other amino acid substitutions at this codon (Gly, Gln, Pro, Leu) have been reported in individuals with hemophilia B and are considered pathogenic (see link to Factor IX database and references therein). Based on available information, the p.Arg226Trp variant is considered to be pathogenic. References: Link to Factor IX database: http://f9-db.eahad.org Chavali S et al. Hemophilia B is a quasi-quantitative condition with certain mutations showing phenotypic plasticity. Genomics. 2009 Dec;94(6):433-7. Hamasaki-Katagiri N et al. Analysis of F9 point mutations and their correlation to severity of haemophilia B disease. Haemophilia. 2012 Nov;18(6):933-40. - |
F9-related disorder Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | Jun 21, 2023 | The F9 c.676C>T variant is predicted to result in the amino acid substitution p.Arg226Trp. This variant also described using legacy nomenclature as p.Arg180Trp; has been reported in multiple individuals with moderate to severe hemophilia B (Giannelli et al. 1994. PubMed ID: 7937052; Hamasaki-Katagiri et al. 2012. PubMed ID: 22639855; Huang et al. 2020. PubMed ID: 32875744; F9 database: http://www.factorix.org/). Different missense variants in the same codon (p.Arg226Gly, p.Arg226Gln, p.Arg226Pro and p.Arg226Leu) have also been reported in individuals with hemophilia B (Giannelli et al. 1994. PubMed ID: 7937052; Hamasaki-Katagiri et al. 2012. PubMed ID: 22639855; Huang et al. 2020. PubMed ID: 32875744; F9 database: http://www.factorix.org/) suggesting that substitution of amino acid residue p.Arg226 is not tolerated. This variant has not been reported in a large population database (http://gnomad.broadinstitute.org), indicating this variant is rare. This variant is interpreted as pathogenic. - |
Hereditary factor IX deficiency disease;C2749016:Thrombophilia, X-linked, due to factor 9 defect Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Invitae | Apr 23, 2022 | This sequence change replaces arginine, which is basic and polar, with tryptophan, which is neutral and slightly polar, at codon 226 of the F9 protein (p.Arg226Trp). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individuals with hemophilia B (PMID: 1346077, 18624698, 19699296, 32875744). This variant is also known as C20518T (180 R>W).. ClinVar contains an entry for this variant (Variation ID: 10590). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive. This variant disrupts the p.Arg226 amino acid residue in F9. Other variant(s) that disrupt this residue have been observed in individuals with F9-related conditions (PMID: 32875744), which suggests that this may be a clinically significant amino acid residue. For these reasons, this variant has been classified as Pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at